Phunware may offer and sell, from time to time, shares of the company's common stock, par value $0.0001 per share, for aggregate gross proceeds of up to $120 million
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is trading higher Tuesday after the company announced three-year results from the ongoing HOPE-2 open-label extension